Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2025)

Contineum Therapeutics has reported Operating Expenses over the past 3 years, most recently at $17.1 million for Q4 2025.

  • Quarterly results put Operating Expenses at $17.1 million for Q4 2025, changed 0.4% from a year ago — trailing twelve months through Dec 2025 was $68.1 million (up 33.72% YoY), and the annual figure for FY2025 was $68.1 million, up 33.73%.
  • Operating Expenses for Q4 2025 was $17.1 million at Contineum Therapeutics, up from $14.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for CTNM hit a ceiling of $18.1 million in Q1 2025 and a floor of $5.1 million in Q1 2023.
  • Median Operating Expenses over the past 3 years was $12.0 million (2023), compared with a mean of $12.7 million.
  • Peak annual rise in Operating Expenses hit 94.13% in 2024, while the deepest fall reached 1.08% in 2024.
  • Contineum Therapeutics' Operating Expenses stood at $9.7 million in 2023, then surged by 76.18% to $17.0 million in 2024, then grew by 0.4% to $17.1 million in 2025.
  • The last three reported values for Operating Expenses were $17.1 million (Q4 2025), $14.9 million (Q3 2025), and $17.9 million (Q2 2025) per Business Quant data.